Decoding 5 Analyst Evaluations For OrthoPediatrics
Portfolio Pulse from Benzinga Insights
OrthoPediatrics (NASDAQ:KIDS) has been evaluated by 5 analysts in the last three months, with a shift towards a more bearish sentiment. The average 12-month price target has been reduced by 12.73% to $38.4, with a high estimate of $50.00 and a low of $31.00. Analysts from Truist Securities and JMP Securities have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. OrthoPediatrics is a medical device company focused on the pediatric orthopedic market, showing a revenue growth of 14.37% as of September 30, 2023, and a net margin of -11.49%. The company's ROE and ROA are -1.22% and -1.06% respectively, with a debt-to-equity ratio of 0.0.
January 25, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
OrthoPediatrics has seen a decrease in the average price target by analysts, indicating a bearish sentiment. However, the company has shown strong revenue growth, which may counterbalance the negative sentiment.
The reduction in the average price target suggests that analysts are less optimistic about the stock's future performance, which could lead to a negative short-term impact on the stock price. However, the strong revenue growth reported by the company could mitigate some of the negative sentiment, as it indicates a solid top-line performance. The net margin, ROE, and ROA figures suggest some challenges in profitability and asset utilization, which could be a concern for investors. The neutral score reflects the balance between positive revenue growth and concerns over profitability and asset efficiency.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100